Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439466 | 0.98 | NR1I2 (0.58) | NR1I2CYP2E1USP30MEN1KMT2A | |
| SCHEMBL2216694 | 0.95 | NR1I2 (0.56) | NR1I2CYP2E1USP30MEN1KMT2A | |
| SCHEMBL12439473 | 0.92 | NR1I2 (0.60) | NR1I2CYP2E1 | |
| SCHEMBL12439447 | 0.91 | NR1I2 (0.60) | NR1I2CYP2E1 | |
| SCHEMBL12439623 | 0.91 | NR1I2 (0.58) | NR1I2CYP2E1USP30MEN1KMT2A | |
| SCHEMBL939293 | 0.90 | NR1I2 (0.62) | NR1I2CYP2E1USP30MEN1KMT2A | |
| SCHEMBL12514501 | 0.89 | NR1I2 (0.42) | NR1I2CYP2E1USP30MEN1KMT2A | |
| SCHEMBL12439472 | 0.89 | NR1I2 (0.62) | NR1I2CYP2E1MEN1KMT2A | |
| SCHEMBL2218529 | 0.89 | NR1I2 (0.54) | NR1I2CYP2E1USP30 | |
| SCHEMBL12439440 | 0.88 | NR1I2 (0.61) | NR1I2CYP2E1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523951-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2523951-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885USP30 3357/4885 |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885USP30 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.